Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 9 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

9 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
July 22, 2021 HCWB P 12,500 $8.00 $100,000 46,785 Direct +36.46% Acquired -99.9% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Dec. 11, 2023 HCWB Stock Option (Right to Buy) Common Stock (14,000) $0.14 Dec. 19, 2029 14,000 Disposed
Nov. 17, 2023 HCWB Stock Option Grant (Right to Buy) Common Stock (15,000) $0.14 Dec. 19, 2029 15,000 Disposed
Jan. 14, 2022 HCWB Stock Option Grant (Right to Buy) Common Stock (1,714) $0.21 Dec. 22, 2030 1,714 Disposed
Jan. 14, 2022 HCWB Stock Option Grant (Right to Buy) Common Stock (1) $0.14 Dec. 19, 2029 1 Disposed
Sept. 8, 2021 HCWB Stock Option (Right to Buy) Common Stock (20,000) $4.31 Sept. 7, 2031 20,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 3 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
July 19, 2021 HCWB Common Stock 34,285 Direct
July 19, 2021 HCWB Stock Option (Right to Buy)→ Common Stock (51,428) 51,428 Direct
July 19, 2021 HCWB Stock Option (Right to Buy)→ Common Stock (8,571) 8,571 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

HCWB

Ph.D. Chief Scientific Officer and Vice President of Clinical Operations
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2022 $238,404 · · · · · $10,166 $248,570

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.